VERONA PHARMA P/S (NASDAQ:VRNA)‘s stock had its “buy” rating reiterated by Wedbush in a research note issued on Friday, TipRanks reports. They currently have a $60.00 target price on the stock.
VRNA has been the subject of a number of other research reports. SunTrust Banks increased their price target on shares of VERONA PHARMA P/S from $29.00 to $34.00 and gave the company a “buy” rating in a report on Tuesday, January 14th. Zacks Investment Research downgraded shares of VERONA PHARMA P/S from a “buy” rating to a “hold” rating in a report on Saturday, January 18th. Finally, ValuEngine lowered shares of VERONA PHARMA P/S from a “buy” rating to a “hold” rating in a research report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $29.44.
Shares of NASDAQ:VRNA opened at $7.28 on Friday. The company has a current ratio of 4.07, a quick ratio of 4.07 and a debt-to-equity ratio of 0.02. VERONA PHARMA P/S has a 12 month low of $3.65 and a 12 month high of $12.89. The company has a 50-day moving average price of $6.01 and a 200 day moving average price of $4.74. The company has a market cap of $87.55 million, a price-to-earnings ratio of -2.76 and a beta of -0.77.
A number of institutional investors have recently bought and sold shares of VRNA. UBS Group AG raised its position in VERONA PHARMA P/S by 801.8% in the 4th quarter. UBS Group AG now owns 10,055 shares of the company’s stock worth $58,000 after purchasing an additional 8,940 shares during the period. Renaissance Technologies LLC purchased a new stake in VERONA PHARMA P/S in the 4th quarter worth about $72,000. IHT Wealth Management LLC raised its position in VERONA PHARMA P/S by 18.1% in the 3rd quarter. IHT Wealth Management LLC now owns 20,460 shares of the company’s stock worth $94,000 after purchasing an additional 3,130 shares during the period. Finally, Wedbush Securities Inc. raised its position in VERONA PHARMA P/S by 24.7% in the 3rd quarter. Wedbush Securities Inc. now owns 30,315 shares of the company’s stock worth $139,000 after purchasing an additional 6,000 shares during the period. 56.28% of the stock is currently owned by institutional investors.
About VERONA PHARMA P/S
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis.
Recommended Story: Stock Symbol
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.